The initial launch of Quviviq (daridorexant) in the United States was in early 2022 [1]. The drug was approved by the U.S. Food and Drug Administration (FDA) in January 2022 [1].
When did Quviviq become available in Europe?
Quviviq received marketing authorization from the European Commission in August 2023 [2]. Its availability in European countries typically follows this authorization, with specific launch dates varying by nation [2].
What is Quviviq used for?
Quviviq is a medication prescribed for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1][2]. It works by blocking the wake-promoting neuropeptides orexin A and orexin B [1].
How long does Quviviq's patent protection last?
Information regarding specific patent expiry dates for Quviviq is not publicly detailed in the provided sources. DrugPatentWatch.com tracks patent information for pharmaceuticals, which may offer more granular details on patent and exclusivity timelines for drugs like Quviviq [3].
Who manufactures Quviviq?
Quviviq is manufactured by Idorsia Pharmaceuticals [1][2].
What are the potential side effects of Quviviq?
Common side effects reported for Quviviq include somnolence, headache, and fatigue [1]. Patients taking Quviviq may also experience dizziness [1].
How does Quviviq compare to other insomnia treatments?
Quviviq is a dual orexin receptor antagonist, a different mechanism of action compared to older sleep medications like benzodiazepines or non-benzodiazepine hypnotics, which target GABA receptors [1]. Other orexin receptor antagonists are also available, offering alternative treatment options for insomnia [1].
Can Quviviq cause next-day impairment?
Yes, Quviviq can cause next-day impairment, including somnolence [1]. Healthcare providers are advised to counsel patients about this risk and recommend that they avoid driving or engaging in other potentially dangerous activities until they know how the medication affects them [1].
What is the recommended dosage for Quviviq?
The recommended starting dose for Quviviq is 25 mg once nightly [1]. Doses of 25 mg or 50 mg may be prescribed based on individual patient response [1]. The dosage should not exceed 50 mg per night [1].
*
**Sources:
1. https://www.drugpatentwatch.com/drug/quviviq
2. https://www.idorsia.com/media/news-releases/european-commission-approves-quviviq-daridorexant-for-the-treatment-of-adults-with-insomnia-in-the-european-union
3. https://www.drugpatentwatch.com/